BONJESTA Drug Patent Profile

When do Bonjesta patents expire, and what generic alternatives are available?

Bonjesta is a drug marketed by Duchesnay and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in BONJESTA is doxylamine succinate; pyridoxine hydrochloride. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the doxylamine succinate; pyridoxine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bonjesta

A generic version of BONJESTA was approved as doxylamine succinate; pyridoxine hydrochloride by ACTAVIS LABS FL INC on August 19^th, 2016.

Summary for BONJESTA

US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	1
Patent Applications:	15
Drug Prices:	Drug price information for BONJESTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BONJESTA
What excipients (inactive ingredients) are in BONJESTA?	BONJESTA excipients list
DailyMed Link:	BONJESTA at DailyMed

See drug prices for BONJESTA

Recent Clinical Trials for BONJESTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Duchesnay Inc.	Phase 3
Health Decisions	Phase 3

See all BONJESTA clinical trials

Pharmacology for BONJESTA

Ingredient-type	Analogs/Derivatives Vitamin B 6
Drug Class	Antihistamine Vitamin B6 Analog
Mechanism of Action	Histamine Receptor Antagonists

Paragraph IV (Patent) Challenges for BONJESTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BONJESTA	Extended-release Tablets	doxylamine succinate; pyridoxine hydrochloride	20 mg/20 mg	209661	1	2018-08-28

US Patents and Regulatory Information for BONJESTA

BONJESTA is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Duchesnay	BONJESTA	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209661-001	Nov 7, 2016		RX	Yes	Yes	9,937,132		Y
Duchesnay	BONJESTA	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209661-001	Nov 7, 2016		RX	Yes	Yes	9,089,489		Y
Duchesnay	BONJESTA	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209661-001	Nov 7, 2016		RX	Yes	Yes	9,375,404		Y

Expired US Patents for BONJESTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Duchesnay	BONJESTA	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209661-001	Nov 7, 2016	7,560,122

International Patents for BONJESTA

When does loss-of-exclusivity occur for BONJESTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Cyprus

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Poland

Portugal

Singapore

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BONJESTA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2003245774	PHARMACEUTICAL DOSAGE FORM BEARING PREGNANCY-FRIENDLY INDICIA
Belgium	1016043	FORME POSOLOGIQUE PHARMACEUTIQUE PORTANT UNE SIGNALETIQUE INDIQUANT UNE PARFAITE INNOCUITE EN CAS DE GROSSESSE.
Canada	2392486	FORME POSOLOGIQUE PHARMACEUTIQUE PORTANT UNE INSCRIPTION POUR LES FEMMES ENCEINTES (PHARMACEUTICAL DOSAGE FORM BEARING PREGNANCY-FRIENDLY INDICIA)

Supplementary Protection Certificates for BONJESTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3185856	CA 2024 00001	Denmark		PRODUCT NAME: COMBINATION OF DOXYLAMINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PYRIDOXINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT. REG. NO/DATE: 66650 20230704; FIRST REG. NO/DATE: NL RVG 128835 20230216
3185856	CR 2024 00001	Denmark		PRODUCT NAME: COMBINATION OF DOXYLAMINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PYRIDOXINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT. REG. NO/DATE: 66650 20230704; FIRST REG. NO/DATE: NL RVG 128835 20230216
3185856	122024000003	Germany		PRODUCT NAME: KOMBINATION AUS DOXYLAMIN, ODER EINES PHARMAZEUTISCH AKZEPTABLEN SALZES DAVON, UND PYRIDOXIN, ODER EINES PHARMZEUTISCH AKZEPTABLEN SALZES DAVON; NAT. REGISTRATION NO/DATE: 7006779.00.00 20230717; FIRST REGISTRATION: NIEDERLANDE RVG 128835 20230216

BONJESTA Market Dynamics and Financial Trajectory

Last updated: August 25, 2026

Bonjesta is a prescription extended-release combination of doxylamine succinate and pyridoxine hydrochloride for nausea and vomiting of pregnancy when conservative measures are inadequate. Its commercial position depends on branded pricing, physician recognition, payer coverage, and protection against generic delayed-release doxylamine-pyridoxine products. The product has a defensible formulation position but limited therapeutic differentiation from Diclegis and lower-cost alternatives.

Public financial disclosure is limited because Bonjesta’s commercial sponsor, Duchesnay USA Inc., is privately held and does not report product-level revenue in SEC filings. A precise historical revenue series, operating margin, or product valuation therefore cannot be established from public filings. The available evidence supports a mature, niche prescription product with recurring demand but material generic and reimbursement pressure.

What is Bonjesta and how does it generate revenue?

Bonjesta contains 20 mg of doxylamine succinate and 20 mg of pyridoxine hydrochloride in an extended-release tablet. The recommended starting dose is one tablet at bedtime, with escalation to two tablets daily when required. It is indicated for nausea and vomiting of pregnancy in patients who do not respond to conservative management.[1]

The commercial revenue model has four components:

Revenue driver	Effect on Bonjesta
Prescription volume	Supported by the high incidence of nausea and vomiting during pregnancy
Net price	Reduced by commercial rebates, Medicaid discounts, and pharmacy benefit management
Payer coverage	Determines whether patients fill Bonjesta or use OTC doxylamine plus vitamin B6
Generic competition	Creates the largest long-term threat to price and market share

Bonjesta’s target population is large, but the addressable branded market is narrower than the prevalence of pregnancy-related nausea. Many patients are treated with dietary measures, pyridoxine alone, generic antiemetics, or OTC doxylamine and pyridoxine. The product therefore competes in a high-volume clinical category but does not capture the full underlying disease population.

When did Bonjesta receive FDA approval?

Bonjesta was approved by the U.S. Food and Drug Administration in November 2016.[2] It followed Diclegis, an earlier delayed-release doxylamine-pyridoxine product approved in 2013.[3]

FDA regulatory timeline

Event	Date	Commercial relevance
Diclegis FDA approval	April 2013	Re-established a prescription delayed-release doxylamine-pyridoxine product in the U.S.
Bonjesta FDA approval	November 2016	Introduced the higher-strength 20 mg/20 mg tablet
Bonjesta marketing period	2016-present	Dependent on physician prescribing and payer access
Generic risk period	Ongoing	Depends on listed patents, certifications, litigation, and FDA approval timing

Bonjesta is a small-molecule drug, not a biologic. Biosimilar competition is therefore irrelevant. The relevant regulatory threat is an abbreviated new drug application, or ANDA, for a therapeutically equivalent delayed-release product.

What patents protect Bonjesta?

Bonjesta’s protection is based primarily on formulation, dosage strength, release characteristics, and use of the doxylamine-pyridoxine combination rather than on new-molecule exclusivity. Doxylamine and pyridoxine are longstanding active ingredients, which limits the value of composition-of-matter protection.

The relevant intellectual-property categories are:

Patent category	Strategic value
Extended-release formulation	Protects the timed delivery of doxylamine and pyridoxine
Dosage-form claims	May distinguish the 20 mg/20 mg Bonjesta tablet from lower-strength products
Combination-product claims	Protects the paired active ingredients in a defined formulation
Method-of-use claims	Covers treatment of nausea and vomiting of pregnancy
Manufacturing claims	May restrict production methods, coating systems, or release profiles

The FDA Orange Book, rather than promotional material or patent databases alone, controls the practical analysis of listed patents and their expiration dates.[4] A complete current patent-expiry conclusion requires reconciliation of the active Orange Book listing, patent-term adjustment, pediatric exclusivity, terminal disclaimers, and any court judgment or settlement.

How strong is the Bonjesta patent estate?

The estate is structurally weaker than a new chemical entity estate because the active ingredients are old and the product’s commercial value rests on formulation and dosing convenience. Formulation patents can still delay generic entry if the claims require a specific release profile or tablet architecture. Their strength depends on claim breadth, prosecution history, prior art, and whether an ANDA applicant can design around the claims.

The estate is stronger against an exact-copy delayed-release product than against:

• Immediate-release doxylamine-pyridoxine combinations
• Separate OTC doxylamine and pyridoxine products
• Alternative prescription antiemetics
• Formulations using different release coatings
• Products relying on a different dosage schedule

When does Bonjesta lose exclusivity?

Bonjesta does not have a meaningful new chemical entity exclusivity period because its active ingredients were previously known. The commercial exclusivity analysis depends on FDA regulatory exclusivity, Orange Book patents, pediatric provisions, and litigation outcomes.

The principal risk is not an abrupt loss of all demand. It is a gradual reduction in branded net price and market share after a therapeutically equivalent generic becomes available. Pregnancy-related nausea is recurrent across annual birth cohorts, so the market can remain commercially relevant after patent expiry even when branded economics deteriorate.

Bonjesta exclusivity factors

Factor	Likely effect
New chemical entity exclusivity	Not a principal protection mechanism
Formulation patents	Main potential barrier to exact generic substitution
Method-of-use patents	May be vulnerable to section viii carve-outs
Pediatric exclusivity	Could add six months if awarded and applicable
ANDA Paragraph IV challenge	Can accelerate litigation and first generic entry
Authorized generic	Could preserve some manufacturer economics while reducing retail price

A fixed commercial-loss date should not be assigned without the current Orange Book patent table and litigation record. Patent expiration, FDA approval, and actual generic launch are separate events.

Are there Paragraph IV challenges to Bonjesta?

A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. If filed, it can trigger patent litigation under the Hatch-Waxman Act and impose a potential 30-month stay on FDA approval, subject to statutory exceptions.[5]

Publicly available information does not establish a widely reported, market-defining Bonjesta Paragraph IV litigation event comparable to major blockbuster drug challenges. The absence of a prominent public case does not eliminate risk. Smaller products can face ANDA litigation that receives limited financial-market coverage.

The practical monitoring points are:

1. FDA Orange Book patent listings.
2. ANDA litigation complaints under 21 U.S.C. § 271(e)(2).
3. Federal district court docket activity.
4. FDA approval letters and tentative approvals.
5. Any settlement providing a licensed generic-entry date.
6. Pharmacy-level substitution after commercial launch.

What generic entry risks exist for Bonjesta?

Generic risk is high in principle because the product uses old active ingredients and treats a condition with established low-cost alternatives. The timing risk is more difficult to quantify because the relevant product must replicate delayed-release performance and satisfy FDA bioequivalence requirements.

Generic launch scenarios

Scenario	Timing	Market effect
No approved equivalent	Before confirmed approval	Bonjesta retains pricing control, subject to payer pressure
Tentative approval only	Patent or exclusivity barrier remains	Limited immediate commercial effect
First approved generic	After regulatory and patent clearance	Rapid price erosion likely
Authorized generic	Parallel or coordinated launch	Lower prices with partial sponsor retention
Multiple generics	Follow-on period	Greater discounting and reduced branded share

A generic product may not need to reproduce Bonjesta’s commercial messaging. It must meet FDA requirements for the same active ingredients, strength, dosage form, route, and therapeutic equivalence. If the label contains protected methods of use, an ANDA sponsor may use a section viii statement to omit those indications rather than challenge the patent directly.[6]

How does Bonjesta compare with Diclegis?

Bonjesta and Diclegis use the same active ingredients but differ in strength and dosing design.

Product	Active ingredients per tablet	FDA approval	Position
Diclegis	10 mg doxylamine succinate / 10 mg pyridoxine HCl	2013	Lower-strength delayed-release product
Bonjesta	20 mg doxylamine succinate / 20 mg pyridoxine HCl	2016	Higher-strength delayed-release product

Bonjesta can reduce pill burden relative to lower-strength dosing, but the clinical category remains highly substitutable. Prescribers can use Diclegis, generic equivalents where available, or separate OTC ingredients. That limits Bonjesta’s ability to command a premium solely from clinical efficacy.

The strongest commercial argument is convenience and adherence. The weakest point is the availability of inexpensive ingredients with a long history of use.

What is the Orange Book status of Bonjesta?

The Orange Book is the controlling FDA source for therapeutic-equivalence evaluations and listed patents or exclusivity associated with approved products.[4] Bonjesta’s relevant listing should be assessed by product name, active ingredients, dosage form, strength, NDA, and sponsor.

Orange Book analysis should distinguish:

• Bonjesta from Diclegis
• Delayed-release tablets from immediate-release products
• Brand listings from authorized generics
• Active patents from expired or delisted patents
• Patent expiry from FDA exclusivity expiry

A formulation patent may remain relevant even when a method-of-use patent is expired. Conversely, a method-of-use listing may have limited practical force if a generic can omit the patented indication through a section viii carve-out.

What is Bonjesta’s financial trajectory?

Bonjesta’s public financial trajectory cannot be measured through audited product-level revenue because Duchesnay is privately held and does not publish a complete Bonjesta income statement. The commercial trajectory is best assessed through market structure rather than reported sales.

Commercial phases

Launch and adoption

The 2016 launch gave Duchesnay a higher-strength formulation positioned around reduced pill burden. Initial growth would have depended on physician education, payer contracting, obstetric prescribing patterns, and brand awareness.

Expansion and normalization

After launch, the product entered a mature specialty-prescription phase. Volume is linked to annual pregnancy incidence rather than chronic treatment duration. Prescription turnover is therefore recurring but short-cycle.

Patent and payer pressure

As patent barriers weaken, payers can move patients toward generic delayed-release products or lower-cost alternatives. Gross sales may remain stable while net revenue declines because of rebates and discounts.

Post-generic economics

After an equivalent generic launch, Bonjesta’s revenue would likely split between residual branded demand, patients with favorable coverage, prescriber preference, and any authorized-generic strategy. The product could remain clinically relevant but would face lower net pricing and reduced negotiating leverage.

What is Bonjesta’s revenue exposure?

Bonjesta is not publicly disclosed as a standalone revenue line by a large publicly traded pharmaceutical company. No reliable public source establishes annual Bonjesta sales, cumulative revenue, EBITDA contribution, or current valuation.

The key financial sensitivities are:

Variable	Financial impact
Prescription count	Drives gross demand
Average selling price	Determines gross revenue
Rebate rate	Reduces net sales
Medicaid and government exposure	Increases statutory discount obligations
Generic launch date	Determines price erosion timing
Sponsor commercialization cost	Affects operating margin
Litigation or licensing expense	Can reduce near-term profitability

The product’s revenue quality is mixed. Demand is medically recurring, but treatment duration is short and substitution options are extensive. That combination supports a durable niche but limits blockbuster economics.

What licensing deals affect Bonjesta?

No major publicly disclosed third-party licensing transaction has established a clear market valuation or royalty framework for Bonjesta. Duchesnay’s commercial position appears principally tied to its own prescription-product platform and U.S. commercialization activities.

Any private distribution, co-promotion, manufacturing, or supply agreement would require contract-level disclosure to quantify. Public evidence does not support assigning a material licensing contribution to Bonjesta’s financial trajectory.

What manufacturing and IP barriers affect generic entry?

Manufacturing complexity is moderate rather than extreme. The product is an oral tablet, not an injectable, implant, or biologic. The main technical barrier is controlled release, including:

• Consistent dissolution performance
• Stability of both active ingredients
• Tablet coating and release-layer reproducibility
• Bioequivalence across the dosing interval
• Scale-up and batch-to-batch control

These barriers can slow development but generally do not create the durable protection associated with complex biologics or device-drug combinations. Once a generic manufacturer solves the formulation and receives approval, manufacturing cost is unlikely to support Bonjesta’s branded price.

Key Takeaways

• Bonjesta is a 20 mg/20 mg delayed-release doxylamine-pyridoxine tablet approved by the FDA in 2016.
• Its commercial value rests on formulation, dosing convenience, brand recognition, and payer access.
• The active ingredients are old, so Bonjesta lacks the protection of a new chemical entity.
• Formulation patents are more important than composition-of-matter patents.
• Generic competition is the principal long-term threat.
• Biosimilar risk does not apply because Bonjesta is a small-molecule oral drug.
• No reliable public product-level revenue series is available because Duchesnay is privately held.
• Bonjesta’s likely financial profile is a recurring niche product with meaningful price risk after generic entry.
• The current Orange Book and federal litigation dockets are required to establish a definitive patent-expiry and Paragraph IV timeline.

FAQs

Is Bonjesta considered a specialty pharmaceutical?

Bonjesta is a prescription product in the obstetric and women’s-health market. It is commercially specialized by indication, but it does not have the manufacturing complexity or biologic profile typically associated with specialty pharmaceuticals.

Can patients buy Bonjesta over the counter?

No. Bonjesta is an FDA-approved prescription product. OTC doxylamine and pyridoxine products are alternatives, but they are not the same branded prescription product or necessarily the same delayed-release formulation.

Does Bonjesta have orphan-drug exclusivity?

No orphan-drug exclusivity is associated with Bonjesta’s indication for nausea and vomiting of pregnancy. The indication affects a broad pregnancy population and does not fit the orphan-drug framework.

What would most increase Bonjesta’s valuation?

A durable delay to generic entry, strong payer coverage, sustained prescription growth, or a licensing transaction with transparent economics would have the greatest potential effect. Public information does not establish that any of these has occurred at a scale sufficient to quantify.

Is Bonjesta clinically differentiated from generic doxylamine-pyridoxine?

The principal differentiation is the branded 20 mg/20 mg delayed-release tablet and its dosing convenience. Clinical differentiation from an FDA-approved therapeutically equivalent generic would generally be limited.

References

1. U.S. Food and Drug Administration. (2023). Bonjesta prescribing information. FDA.

2. U.S. Food and Drug Administration. (2016). Bonjesta approval information. Drugs@FDA.

3. U.S. Food and Drug Administration. (2013). Diclegis approval information. Drugs@FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417.

6. U.S. Food and Drug Administration. (2018). Abbreviated new drug application submissions: Refuse-to-receive standards guidance for industry. FDA.